Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2041148 | 0.91 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL31134235 | 0.91 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL31134232 | 0.91 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2041146 | 0.91 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2043609 | 0.91 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL27771931 | 0.86 | KCNH2 (0.51) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL5516148 | 0.85 | TSHR (0.46) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14763450 | 0.83 | SLC6A3 (0.44) | SLC6A3SLC6A4 | |
| SCHEMBL2585801 | 0.82 | SLC6A3 (0.41) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4333611 | 0.82 | KCNH2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048878-B2 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-01 | — | — | US | disclosed |
| US-7737141-B2 | such as -{4-{1-[(S)-1-(4-fluorophenyl)ethyl]-2-oxopiperidin-(3E)-ylidenemethyl}-2-methoxyphenyl}-5-methyl-1-(phosphonooxymethyl)-3H-imidazol-1-ium trifluoroacetate, which inhibit the synthesis of amyloid precursor proteins; treatment of Alzheimer's disease, Down syndrome or amyloidosis | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-2048143-A1 | PRODRUG OF CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090048213-A1 | Prodrug of cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2009-02-19 | — | — | US | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | SLC6A3 1834/4885SLC6A4 1800/4885SLC6A2 1304/4885 |
| US-20090048213-A1 | Prodrug of cinnamide compound | BTK, CNKSR1, AKT1 | SLC6A3 4495/4885SLC6A4 4434/4885SLC6A2 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.